Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amar Gupta

Plastic Surgery Within the Head and Neck Riverside, CA Medical Doctor

NPI 1912340159 CMS profile 2789505

6850 Brockton Ave Ste 108, Riverside, CA 92506

Open in the dashboard

General payments

$25,908

57 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amar Gupta of Riverside, CA is reported in the CMS Open Payments database as having received $25,908 across 57 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Plastic Surgery Within the Head and Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,097 24
2024 General $6,600 24
2023 General $62 3
2022 General $111 4
2021 General $39 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amar Gupta
  • Plastic Surgery Within the Head and Neck median
  • Middle half of Plastic Surgery Within the Head and Neck
  • National median

In program year 2025, general payments to Amar Gupta were reported at $19,097. Among 103 Plastic Surgery Within the Head and Neck profiles paid that year, the median was $300 and the middle half received between $115 and $580.

Show as a table
Year Amar Gupta Plastic Surgery Within the Head and Neck median Middle half National median
2019 $0 $270 $76–$780 $163
2020 $0 $172 $52–$421 $114
2021 $39 $227 $64–$753 $132
2022 $111 $338 $112–$800 $149
2023 $62 $303 $89–$723 $160
2024 $6,600 $289 $115–$714 $164
2025 $19,097 $300 $115–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Aerin Medical Inc. $24,387 40 payments
  2. Integra LifeSciences Corporation $1,300 7 payments
  3. Neurent Medical Limited $71 4 payments
  4. Stryker Corporation $69 2 payments
  5. Allergan Inc. $42 2 payments
  6. GlaxoSmithKline, LLC. $39 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $21,050 13 payments
  2. Travel and Lodging $3,135 9 payments
  3. Food and Beverage $1,723 35 payments
Products named General payments · program years 2021–2025
  1. VIVAER STYLUS $24,387 40 payments
  2. GENTRIX $636 3 payments
  3. Integra Recon-Skin And Wound $494 2 payments
  4. Integra Recon-Skin And Wound $494 2 payments
  5. Integra Recon-Skin And Wound $494 2 payments
  6. INTEGRA DERMAL REGENERATION TEMPLATE $494 2 payments
  7. PRIMATRIX $494 2 payments
  8. RHINAER STYLUS $315 10 payments
  9. ACCLARENT AERA $170 2 payments
  10. INSPIRA AIR $170 2 payments
  11. Other $632 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

65

Median for Otolaryngology: 297

Drug cost

$3,366

Median for Otolaryngology: $6,314

Branded share of claims

27.7%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 18 $2,359
Ipratropium Bromide Generic 18 $865
Methylprednisolone Generic 14 $74
Amoxicillin Generic 15 $68

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$57,085

Medicare's payments for the services billed

Medicare patients

69

Average age 73

Services billed

259

41 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 36%
Ischemic heart disease 22%
COPD 22%
Chronic kidney disease 20%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

57 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery Within the Head and Neck in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record